Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kava AERs not linked to fatalities

This article was originally published in The Tan Sheet

Executive Summary

Two reports of hepatic toxicity associated with kava and appearing in CDC's Nov. 29 Morbidity & Mortality Weekly Report were not fatalities, as reported in 1"The Tan Sheet" Dec. 2, 2002, p. 6. Patients in both case reports recovered following their illnesses...

You may also be interested in...



Kava fatalities in MMWR

Possibility of hepatic toxicity associated with use of kava products reported in CDC's Nov. 29 Morbidity & Mortality Weekly Report. MMWR summarizes two case reports: the first involves a 45-year-old woman who underwent liver transplantation after being hospitalized for jaundice and hepatitis following regular use of a kava-containing dietary supplement; the second involves a 14-year-old girl diagnosed with scleral icterus and acute hepatitis following a four-month period of semi-regular kava use. FDA issued a consumer advisory on the botanical earlier this year (1"The Tan Sheet" April 1, 2002)...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Topics

UsernamePublicRestriction

Register

PS094908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel